 Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company aiming to develop novel therapies for immune-mediated diseases with its lead candidate Reproxalap finishing up its Phase 3 multi-trial strategy by FYE 2022. Aldeyra has a large pipeline of 4 clinical-stage therapeutics and 1 pre-clinical stage therapeutic all spread across 10 indications split between ocular and systemic diseases. 